Loading
A phase 1/2 trial of fOLFIRI (5-FU, leucovorin, irinotecan) in lung cancer, run by Washington University School of Medicine, now recruiting.
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) is a phase 1/2, interventional study registered as NCT07155200 by Washington University School of Medicine, with a registry enrolment figure of 42 participants, started 2025-12-18 and due to reach its primary completion in 2028-07-31. Interventions recorded: Cirtuvivint; Irinotecan. Conditions listed: Small-cell Lung Cancer; Small Cell Lung Carcinoma; Small Cell Lung Cancer. Primary outcome: Recommended Phase II dose (RP2D) (Phase I only); Objective response rate (ORR) per RECIST criteria (Phase II and RP2D only). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed small cell lung cancer that has progressed on at least one line of prior platinum-based chemotherapy, given with or without anti-PD-(L)1 therapy". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.